Table 2.
Cox Regression Analysis for Adverse Outcomes Between HFrecEF and Persistent HFrEF Groups
| Clinical outcomes | Unadjusted | Fully adjusted * | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Cardiovascular death or heart failure hospitalization | … | … | … | … | … | … |
| HFrecEF group | 1 | reference | NA | 1 | reference | NA |
| Persistent HFrEF group | 3.479 | 2.422–4.999 | <0.001 | 2.734 | 1.823–4.102 | <0.001 |
| Cardiovascular death | … | … | … | … | … | … |
| HFrecEF group | 1 | reference | NA | 1 | reference | NA |
| Persistent HFrEF group | 3.606 | 2.017–6.448 | <0.001 | 2.597 | 1.331–5.067 | 0.005 |
| Heart failure hospitalization | … | … | … | … | … | … |
| HFrecEF group | 1 | reference | NA | 1 | reference | NA |
| Persistent HFrEF group | 3.454 | 2.186–5.460 | <0.001 | 2.916 | 1.777–4.786 | <0.001 |
HFrecEF indicates heart failure with recovered ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; and NA, not applicable.
*
Adjusted for age, body weight, systolic blood pressure, heart rate, atrial fibrillation, coronary artery disease, diabetes, hemoglobin, urea, B‐type natriuretic peptide, high‐sensitivity troponin I, left ventricular end‐diastolic diameter, mitral Doppler early velocity/mitral annular early velocity, time interval between echocardiograms, β‐blockers, renin‐angiotensin‐aldosterone system blockers, aspirin, spironolactone, loop diuretic, statins, nitrate, and cardiac resynchronization therapy.